Company intelligence / Profile preview

ANA Therapeutics

Silicon Valley, California, United States

Ownership: Private
Development stage: Other

Overview

Before its acquisition, ANA Therapeutics was developing ANA-001, an oral capsule formulation of niclosamide repurposed as an antiviral/anti‑inflammatory for hospitalized patients with moderate to severe COVID‑19 (not requiring ventilators), in a two‑part Phase 2/3 trial initiated in October 2020 under the 505(b)(2) pathway.[1] The first 60‑patient Phase 2 portion focused on safety and tolerability with secondary efficacy and PK endpoints; topline data were expected in 2021, but no public late‑stage efficacy results are available in the acquisition materials.[1]

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Quotient SciencesNeuroBo Pharmaceuticals

Beyond the preview

Go deeper on ANA Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANA Therapeutics.

Explore the full profile